Double-blind, Randomized, Multi-centre Phase II Study to Evaluate the Efficacy and Safety of Topically Applied LAS41007 Once Daily and LAS41007 Twice Daily Versus LAS106521 Gel Twice Daily in the Treatment of Actinic Keratosis Grade I to II.
Phase of Trial: Phase II
Latest Information Update: 05 Jun 2015
At a glance
- Drugs LAS 106521 (Primary) ; LAS 41007 (Primary)
- Indications Actinic keratosis; Skin cancer
- Focus Therapeutic Use
- Sponsors Almirall S.A.
- 05 Mar 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 17 Dec 2009 New profile.
- 23 Oct 2009 New trial record